An investigation for investors in Cellectis SA (ADR) (NASDAQ:CLLS) shares over potential securities laws violations by Cellectis SA (ADR) (NASDAQ:CLLS was announced.
San Diego, CA -- (SBWIRE) -- 09/28/2017 -- Cellectis SA is under investigation over possible violations of securities laws. The investigation was announced for investors in NASDAQ:CLLS shares in connection with certain financial statements made by Cellectis SA.
Investors who purchased shares of Cellectis SA (ADR) (NASDAQ:CLLS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Cellectis SA (ADR) (NASDAQ:CLLS) concerning whether a series of statements by Cellectis SA (ADR) (NASDAQ:CLLS regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On September 5, 2017, Cellectis SA announced the U.S. Food and Drug Administration's suspension of two early-stage studies for the Company's experimental blood cancer treatment UCART123, following the death of a patient.Shares of Cellectis SA (ADR) (NASDAQ:CLLS) declined on September 5, 2017 to $23.89 per share.
Those who purchased shares of Cellectis SA (ADR) (NASDAQ:CLLS) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com